SSTR5 antagonist alone is effective at lowering blood glucose when glucose is delivered orally but not intraperitoneally (Jepsen et al., 2021), which is in line with our findings that triple treatment protects against olanzapine-induced glucose intolerance but not olanzapine-induced hyperglycemia. The gene discussed is SSTR5; the disease is Hyperglycemia.